for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Big Rock Partners Acquisition Corp

BRPA.OQ

Latest Trade

30.82USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.50

 - 

76.87

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
30.82
Open
--
Volume
--
3M AVG Volume
0.93
Today's High
--
Today's Low
--
52 Week High
76.87
52 Week Low
10.50
Shares Out (MIL)
2.69
Market Cap (MIL)
96.51
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Neurorx, Inc. And Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe To Support Proposed Business Combination

NeuroRx And Relief Conclude Enrollment In Phase 2B/3 Trial Of Rlf-100™ For Critical COVID-19

Big Rock Partners Acquisition Says Lori Wittman Resigned As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Big Rock Partners Acquisition Corp

Big Rock Partners Acquisition Corp. is a blank check company. The Company is formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has not commenced any business operation and has not generated any revenue.

Industry

Misc. Financial Services

Contact Info

2645 N Federal Hwy Ste 230

DELRAY BEACH, FL

33483-6111

United States

+1.310.7342300

https://www.bigrockpartners.com/spac/spac_aboutus.html

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
34.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
96.50
LT Debt To Equity (MRQ)
96.50
Return on Investment (TTM)
-2.35
Return on Equity (TTM)
-2.28

Latest News

Latest News

Swiss pharma firm Relief, U.S. partner fight after hopes dented for COVID-19 drug

A Swiss company whose market capitalization rose at one time to more than 1.5 billion Swiss francs ($1.6 billion) on hopes an old drug it owned would succeed against COVID-19 is embroiled in a dispute with U.S. partner NeuroRx, it said in a statement.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up